- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07937774
Traditional Chinese Medicine Augmentation Therapy for Obsessive-Compulsive Disorder (TCMA-OCD)
Study of Traditional Chinese Medicine Augmentation Therapy for Obsessive-Compulsive Disorder With Nonresponse to Initial Treatment
Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by recurrent intrusive obsessive thoughts, urges, and ritualized compulsive behaviors. OCD often follows a chronic and protracted course with a high risk of relapse and is frequently accompanied by comorbid anxiety, depression, and other negative emotional symptoms, resulting in substantial impairment in occupational functioning, interpersonal relationships, and family and social functioning.Integrative treatment combining traditional Chinese medicine (TCM) and Western medicine may help address several limitations of conventional monotherapy, including suboptimal treatment response rates, medication-related adverse effects, the limited diversity of available therapeutic approaches, and insufficiently individualized treatment strategies, thereby offering potential clinical benefits.Chaixia Dingzhi Powder, the investigational Chinese herbal formula used in this study, was developed based on the formulation principles of two classical TCM prescriptions, Xiaoyao San (Free and Easy Wanderer Powder), documented in the Taiping Huimin Heji Jufang (Formulary of the Pharmacy Service for Benefiting the People in the Taiping Era), and Banxia Houpo Tang (Pinellia and Magnolia Bark Decoction), recorded in the Jingui Yaolue (Essentials from the Golden Cabinet). The formula was further modified according to the TCM pathophysiological characteristics of the target population, particularly liver qi stagnation with spleen deficiency, impaired qi movement, and the interaction of phlegm and qi stagnation.Therefore, this study aims to further investigate the efficacy and safety of Chaixia Dingzhi Powder as an adjunctive traditional Chinese medicine (TCM) treatment in patients with obsessive-compulsive disorder (OCD) who have demonstrated nonresponse to initial SSRI treatment, while maintaining their existing SSRI therapy at an adequate therapeutic dose or the maximum tolerated dose.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Lanying LIU
- Telefonnummer: 13516816012
- E-post: balindaliu@126.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
1)Aged 16-65 years; 2)Meet the diagnostic criteria for obsessive-compulsive disorder (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); 3)Have received continuous SSRI monotherapy at the maximum recommended dose or maximum tolerated dose for at least 8 consecutive weeks; 4)Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score >12 or a Clinical Global Impression-Severity (CGI-S) score ≥3; 5)Meet the traditional Chinese medicine (TCM) syndrome differentiation criteria for liver qi stagnation and spleen deficiency.
Exclusion Criteria:
1)Meet the DSM-5 diagnostic criteria for any psychiatric disorder other than obsessive-compulsive disorder (OCD), with the exception of obsessive-compulsive personality disorder (OCPD); 2)Meet the criteria for treatment-resistant obsessive-compulsive disorder (TR-OCD) as defined in the Chinese Guidelines for the Prevention and Treatment of Obsessive-Compulsive Disorder; 3) Meet the traditional Chinese medicine (TCM) syndrome differentiation criteria for any syndrome other than liver qi stagnation and spleen deficiency; 4)Women who are pregnant, planning to become pregnant in the near future, or breastfeeding; 5)Have a history of substance abuse within the past 12 months; 6) Have a history of severe drug allergies; 7)Have any other condition that, in the investigator's judgment, makes them unsuitable for participation in the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Control Group
Placebo Group |
Participants will receive Chai-Xia Ding-Zhi Powder placebo as an adjunctive treatment for 8 weeks while continuing SSRIs at their original dosage. |
|
Experimentell: Intervention Group
Chai-Xia Ding-Zhi Powder Group |
Participants will receive Chai-Xia Ding-Zhi Powder as an adjunctive treatment for 8 weeks while continuing SSRIs at their original dosage. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Y-BOCS Score
Tidsram: 8 weeks
|
8 weeks
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2026-92
- ZDYN-2024-A-013 (Annat bidrag/finansieringsnummer: National Administration of Traditional Chinese Medicine (NATCM))
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .